11 completed, 2 terminated, 1 unknown, 1 withdrawn. 5 Phase 4, 3 Phase 3, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 5 | Completed 3, Terminated 1, Withdrawn 1 |
| Phase 3 | 3 | Completed 2, Terminated 1 |
| Not applicable | 1 | Completed 1 |
Follow Alcohol Withdrawal Syndrome: new trials by email Literature Review of Alcohol Withdrawal Syndrome trials Research Report on Alcohol Withdrawal Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of Clinical and Biochemical Variables Over Morbidity and Mortality in Alcohol Withdrawal Syndrome Patients Study Cohort - Alcohol Withdrawal Syndrome | Unknown | Hospital General de Mexico | 195 | 2024-09-09 | 2024-09-19 | |
| Evaluation of a Predictive Score for the Onset of Moderate to Severe Alcohol Withdrawal Syndrome, the PAWSS, in a Population of Intensive Care Patients at Brest University Hospital Alcohol Withdrawal Syndrome | Completed | University Hospital, Brest | 403 | 2022-06-27 | 2024-08-15 | |
| Portrayal of Hospital Alcohol Detoxification in France Stay for alcohol detoxification - Alcohol Use Disorder, Addiction | Completed | University Hospital, Montpellier | 50000 | 2021-05-01 | 2021-10-19 | |
| Alcohol Withdrawal Syndrome Treated With Adjunctive Phenobarbital or Ketamine Ketamine, Phenobarbital, Lorazepam - Alcohol Withdrawal Syndrome | Phase 4 | Withdrawn | Santa Barbara Cottage Hospital | 2019-04-12 | 2019-09-19 | |
| MAGnesium Adjunction in Alcohol Withdrawal Syndrome: a Multicenter Assessment (MAGMA) Magnesium, Placebo Oral Tablet - Alcohol Withdrawal Syndrome | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 105 | 2017-11-16 | 2021-12-21 |
| Assessment of Valproate on Ethanol Withdrawal Valproate, Lorazepam - Alcohol Dependence, Alcohol Withdrawal Syndrome | Phase 4 | Terminated | CAMC Health System | 3 | 2017-07-11 | 2026-08-18 |
| Gabapentin for Alcohol Withdrawal Syndrome Gabapentin, Benzodiazepines, Divalproex Sodium - Alcohol Withdrawal Syndrome | Phase 4 | Completed | Mayo Clinic | 88 | 2017-02-01 | 2022-03-24 |
| Assessment of Energetic Resonance by Cutaneous Stimulation on Withdrawal Alcohol Symptoms. Energetic Resonance by Cutaneous Stimulation - Alcohol Withdrawal Syndrome | Not applicable | Completed | Hospices Civils de Lyon | 43 | 2014-05-01 | 2017-08-23 |
| Preventing Alcohol Withdrawal Syndrome With Oral Baclofen Baclofen, Placebo - Alcohol Withdrawal Syndrome | Phase 3 | Terminated | Denver Health and Hospital Authority | 102 | 2014-03-15 | 2018-05-23 |
| Treatment of Alcohol Withdrawal Syndrome With Alpha-2 Agonists and/or Anticonvulsants BZDP-Sparing Protocol, BZDP-Based Protocol - Alcohol Withdrawal Syndrome | Completed | Stanford University | 30 | 2013-08-01 | 2022-06-30 | |
| Clinical Quality Improvement of Benzodiazepine-Resistant Alcohol Withdrawal Syndrome Diazepam - Alcohol Withdrawal Syndrome | Completed | University of Pittsburgh | 792 | 2012-07-01 | 2016-01-13 | |
| The "Prediction of Alcohol Withdrawal Severity Scale" (PAWSS) Alcohol Withdrawal Syndrome | Completed | Stanford University | 409 | 2012-05-01 | 2015-01-30 | |
| Efficacy and Safety of Levetiracetam in the Inpatient Treatment of Alcohol Withdrawal Syndrome Levetiracetam, Placebo - Alcohol Withdrawal Syndrome | Phase 3 | Completed | Charite University, Berlin, Germany | 120 | 2006-01-01 | 2009-12-30 |
| Comparative Study of Gamma-hydroxy Butyrate Versus Oxazepam in the Treatment of Alcohol Withdrawal Syndrome Sodium Oxybate (SMO), Oxazepam - Alcohol Withdrawal Syndrome, Alcohol Dependence | Phase 4 | Completed | Catholic University of the Sacred Heart | 127 | 2002-02-01 | 2014-03-18 |
| Treatment of Alcohol Withdrawal in Hospital Patients Lorazepam (drug), Lorazepam - Alcohol Withdrawal Syndrome | Phase 4 | Completed | Virginia Commonwealth University | 183 | 2001-04-01 | 2016-04-11 |
Alcoholism (5) · Alcohol Withdrawal Delirium (2) · Alcohol Withdrawal Seizures (2) · Behavior, Addictive (1) · Delirium (1) · Magnesium Deficiency (1) · Substance Withdrawal Syndrome (1) · Tremor (1) · Wounds and Injuries (1)
Chemically-Induced Disorders (7) · Mental Disorders (7) · Substance-Related Disorders (7) · Alcohol-Related Disorders (6) · Nervous System Diseases (3) · Neurologic Manifestations (3) · Pathological Conditions, Signs and Symptoms (3) · Signs and Symptoms (3) · Alcohol-Induced Disorders (2) · Alcohol-Induced Disorders, Nervous System (2) · Neurotoxicity Syndromes (2) · Poisoning (2) · Seizures (2) · Substance Withdrawal Syndrome (2) · Behavior (1)
Lorazepam (4) · Valproic Acid (2) · Baclofen (1) · Benzodiazepines (1) · Chlordiazepoxide (1) · Cohort Studies (1) · Diazepam (1) · Ethanol (1) · Gabapentin (1) · Ketamine (1) · Levetiracetam (1) · Magnesium (1) · Oxazepam (1) · Pharmaceutical Preparations (1) · Phenobarbital (1)
Stanford University (2) · Assistance Publique - Hôpitaux de Paris (1) · CAMC Health System (1) · Catholic University of the Sacred Heart (1) · Charite University, Berlin, Germany (1) · Denver Health and Hospital Authority (1) · Hospices Civils de Lyon (1) · Hospital General de Mexico (1) · Mayo Clinic (1) · Santa Barbara Cottage Hospital (1) · University Hospital, Brest (1) · University Hospital, Montpellier (1) · University of Pittsburgh (1) · Virginia Commonwealth University (1)
United States (7) · France (4) · Austria (1) · Germany (1) · Italy (1) · Mexico (1)
Audis Bethea, PharmD, BCPS (1) · Claude Augustin-Normand, Dr (1) · Daniel B Heppe, MD (1) · Giovanni Addolorato, MD (1) · Jose Maldonado, MD (1) · Jose R Maldonado, MD (1) · Martin Schaefer, MD (1) · Michael F. Weaver, MD (1) · Noah Stites-Hallet, MD (1) · Otto Lesch, MD, Prof. (1) · Ruth E Bates, MD (1)
PMID 16785215, PMID 20944765, PMID 20951277, PMID 21105289, PMID 22898443, PMID 24657098, PMID 24996524, PMID 37469099
2016 (1), K23AA000222 (1)